Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.03), $0.14 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $14.41 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.